NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Freeport-McMoRan Inc. ("Freeport-McMoRan Inc." or the "Company") (NYSE: FCX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Freeport-McMoRan Inc. investors who were adversely affected by alleged securities fraud between February 15, 2022 and September 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/ ...

Core Viewpoint - A class action securities lawsuit has been filed against CarMax, Inc. alleging securities fraud that affected investors between June 20, 2025, and November 5, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that defendants made false statements regarding CarMax's growth prospects, suggesting that earlier growth was due to temporary factors related to customer behavior influenced by tariff speculation [2]. - It is alleged that the statements made by defendants about CarMax's business operations and future prospects were materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 2, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Gauzy Ltd. for alleged violations of securities laws, specifically related to misleading statements made by the company regarding its financial health and debt obligations [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to securities purchased by investors between March 11, 2025, and November 13, 2025, during which the company allegedly made false and misleading statements [2]. - Investors are encouraged to contact the Schall Law Firm before February 6, 2026, to discuss their rights and potential participation in the lawsuit [2][3]. Group 2: Allegations Against the Company - The complaint alleges that Gauzy's subsidiaries in France were unable to repay debts as they became due, leading to potential defaults on senior secured debt facilities [4]. - The company's public statements during the class period are claimed to be false and materially misleading, resulting in investor damages once the truth was revealed [4].

Core Insights - CarMax, Inc. is a leading retailer of used vehicles in the U.S., operating through two segments: CarMax Sales Operations and CarMax Auto Finance, known for no-haggle pricing and comprehensive vehicle inspections [1] - The company is currently facing a class action securities lawsuit alleging securities fraud, which could impact investor sentiment and stock performance [3] - Evercore ISI has set a price target of $37 for CarMax, indicating potential downside from its current trading price of $39.26, which reflects a 5.76% premium over the target [2][5] - The stock has shown significant volatility, with a 52-week high of $91.25 and a low of $30.26, indicating active trading and investor interest [4][5] - CarMax's market capitalization is approximately $5.98 billion, with a trading volume of 3,230,319 shares on the NYSE [4]

Core Viewpoint - The Freeport-McMoRan Inc. class action lawsuit alleges violations of the Securities Exchange Act of 1934, focusing on safety issues at the Grasberg mine and the subsequent impact on stock prices [1][3]. Group 1: Class Action Details - The class action lawsuit is titled Reed v. Freeport-McMoRan Inc., and it includes purchasers of Freeport-McMoRan securities from February 15, 2022, to September 24, 2025 [1]. - Investors have until January 12, 2026, to seek appointment as lead plaintiff in the lawsuit [1][7]. Group 2: Allegations Against Freeport-McMoRan - The lawsuit claims that Freeport-McMoRan failed to ensure adequate safety at the Grasberg Block Cave mine, which heightened risks for workers [3]. - It is alleged that the company did not disclose the risks associated with safety failures, leading to regulatory, litigation, and reputational risks [3]. Group 3: Incident and Stock Impact - On September 9, 2025, Freeport-McMoRan reported a significant incident at the Grasberg mine, leading to a nearly 6% drop in stock price [4]. - Following the revelation of fatalities and ongoing search efforts for missing team members on September 24, 2025, the stock price fell nearly 17% [5]. - An article published on September 25, 2025, indicated that the production halt could strain relations with the Indonesian government, resulting in an additional stock price drop of over 6% [6]. Group 4: Company Background - Freeport-McMoRan is engaged in mining operations in North America, South America, and Indonesia, with significant operations at the Grasberg mine in Papua, Indonesia [2].

PHILADELPHIA, Dec. 9, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead ...

Core Viewpoint - The Perrigo Company plc is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding its financial health and the state of its acquired infant formula business [1][3]. Group 1: Class Action Details - The class action lawsuit is titled French v. Perrigo Company plc and covers securities purchased between February 27, 2023, and November 4, 2025 [1]. - Investors have until January 16, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Perrigo and its executives made false statements and failed to disclose critical issues regarding the infant formula business acquired from Nestlé [3]. Group 2: Allegations Against Perrigo - The complaint states that the acquired infant formula business suffered from significant underinvestment, requiring substantial capital expenditures beyond initial estimates [3]. - Manufacturing deficiencies were reported in the facility, leading to overstated financial results, including earnings and cash flow [3]. - On February 27, 2024, Perrigo disclosed additional costs of $35 million to $45 million for remediation, resulting in a 50% decline in earnings per share compared to the previous year [4]. Group 3: Financial Impact - On May 7, 2024, Perrigo reported net sales of $91 million, a decrease of 34.5%, attributed to lower shipments as the company addressed remediation plans [5]. - The gross margin fell to 36.5%, a decline of 90 basis points, with a significant impact from the infant formula business [5]. - On August 6, 2025, Perrigo's adjusted gross profit decreased by $30 million, or 6.9%, with a reported gross margin of 34.4%, down 260 basis points [6]. Group 4: Strategic Review and Outlook - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and reassessed its previously announced investment of $240 million [7]. - The company slashed its fiscal year 2025 outlook, projecting net sales growth of -2.5% to -3%, down from an expected 0% to 3% [7]. - Expected adjusted diluted earnings per share were revised to a range of $2.70 to $2.80, significantly lower than the previous range of $2.90 to $3.10 [7].

Core Viewpoint - The law firm Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Stride, Inc. for alleged violations of the Securities Exchange Act of 1934, involving misleading statements and non-disclosure of critical operational issues during the specified class period [1][3]. Summary by Sections Class Action Details - Purchasers or acquirers of Stride, Inc. securities from October 22, 2024, to October 28, 2025, have until January 12, 2026, to seek lead plaintiff status in the class action lawsuit [1]. - The lawsuit is titled MacMahon v. Stride, Inc., No. 25-cv-02019 (E.D. Va.) [1]. Allegations Against Stride - The lawsuit alleges that Stride inflated enrollment numbers by retaining "ghost students," cut staffing costs by overloading teachers, ignored compliance requirements, suppressed whistleblowers, and lost existing and potential enrollments [3]. - A complaint filed by the Gallup-McKinley County Schools Board of Education against Stride included allegations of fraud and deceptive practices, which led to a nearly 12% drop in Stride's stock price [4]. - Following a report on poor customer experience leading to higher withdrawal rates and lower conversion rates, Stride estimated a loss of 10,000-15,000 enrollments, resulting in a more than 54% decline in stock price [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Stride securities during the class period to seek lead plaintiff status, which enables them to act on behalf of other class members [6]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7].

Core Viewpoint - A class action lawsuit has been filed on behalf of shareholders of Gauzy Ltd. due to alleged securities fraud during the specified class period from March 11, 2025, to November 13, 2025 [1] Group 1: Company Developments - On November 14, 2025, Gauzy announced the initiation of French law insolvency proceedings for three of its subsidiaries in France, aimed at preserving business operations and repaying creditors [3] - The commencement of these insolvency proceedings constitutes a default under the Company's existing senior secured debt facilities, which could lead to further financial complications if not addressed [3] - The Company will not release its third-quarter financial results as previously scheduled due to the ongoing insolvency proceedings [3] Group 2: Market Reaction - Following the announcement of insolvency proceedings, Gauzy's share price dropped by $2.00, or 49.8%, over two trading days, closing at $2.02 per share on November 17, 2025, with unusually high trading volume [4] Group 3: Lawsuit Details - The class action lawsuit alleges that during the class period, the defendants made materially false and misleading statements and failed to disclose critical adverse facts about the Company's financial health and operations [5] - Specific allegations include the failure to disclose that three French subsidiaries were unable to meet their debts, the likelihood of insolvency proceedings, and the potential triggering of defaults under senior secured debt facilities [5]

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate in the lawsuit [3]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years, highlighting its expertise in complex securities cases [4].